Antidepressant Treatment Resistance is Associated with Increased Inflammatory Markers in Patients with Major Depressive Disorder

Major Depressive Disorder (MDD) affects approximately 10% of the US adult population and is the leading cause of disability worldwide (Friedrich, 2017; Global Burden of Disease Study, 2015). Despite recent advances in understanding the pathophysiology of MDD, approximately 30% of patients with MDD remain treatment refractory following multiple treatment trials with currently available antidepressant medications (Rush et al., 2006).

Source: Psychoneuroendocrinology - May 19, 2018 Category: Psychiatry Authors: Ebrahim Haroon, Alexander W. Daguanno, Bobbi J. Woolwine, David R. Goldsmith, Wendy M. Baer, Evanthia C. Wommack, Jennifer C. Felger, Andrew H. Miller Source Type: research